Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
NCT03722108 · UNICANCER · PHASE1/PHASE2 · terminated · last registry update 2023-10-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Unfavorable benefit-risk balance in the experimental arm following the IDMC for intermediate efficacy and safety analysis” | – | Registry record, UNICANCER |
Also happening at the time. Not shown to be a cause.
No drug target was found for this trial's interventions, so there is no same-target timeline.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision